Consistently, we previously found that patients with MDS harboring U2AF1 mutations had a shorter overall survival compared with those without a U2AF1 mutation, and patients with U2AF1 mutations usually had a higher risk of AML transformation [10]. Here, U2AF1 is linked to myelodysplastic syndrome.